Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Biotechnology

Healthcare
$42.53 -1.86%

-$0.62 today

Market cap
$800.84M
Beta
1.18
P/E (TTM)
1.7
EPS (TTM)
$19.78
52W Low $18.14High $52.24

Volume 0.24M

Average 0.36M

RIGL Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Rigel Pharmaceuticals, Inc.NASDAQ: RIGL

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables growth accelerates

Q1 FY2026 accounts receivables of $1.82M rose 2573.5% year over year, ahead of the -40.2% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -25.8% a year.

Context

  • Accounts receivables amounted to 3.4% of revenue in FY2025, down 2.7 pp from a year earlier.
  • Accounts receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +2573.5% holds above the trailing-twelve-month pace of -40.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.82M+131.1% QoQ
Last fiscal yearDec 2025
-$10.15M-8.3% YoY
LTMMar 2026
-$8.4M-40.2% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2573.5%——
1 year-8.3%——
3-year CAGR-25.8%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(10.15M) USD
Year-over-year change
+8.3%

Accounts Receivables vs competitors

How RIGL compares with its peers on the latest reported figures

  • RIGL's LTM Mar 2026 accounts receivables of $8.4M is the 3rd largest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of -40.2% is the 4th highest of 6, against a peer median of -7.6%.
  • Accounts receivables amounts to 2.8% of revenue for RIGL, versus a peer median of 14.8%.
RIGL Competitors Peer median
Accounts Receivables for RIGL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EXELExelixis, Inc.LTM Jul 2026$29.86M -128.6%—1.2%
VSTMVerastem, Inc.LTM Mar 2026$10.16M -39169.2%—20.5%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$8.4M -40.2%-25.8%2.8%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$5.15M -7.6%-45.1%14.8%
MREOMereo BioPharma Group plcLTM Mar 2026$345.69K +257.1%—69.1%
CRDFCardiff Oncology, Inc.LTM Mar 2026$214K +2045.5%—40.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$0 ——0.0%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$0 ———
ANLAdlai Nortye Ltd.LTM Jun 2024$0 ——0.0%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$0 ———
Peer median (excluding RIGL) $0-7.6%-45.1%14.8%

Competitors are the stored peer set for RIGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(17.91M)(58.57M)(25.09M)17.49M367.02M
Depreciation & Amortization1.16M998K1.24M2.23M2.42M
Deferred Income Tax0000(245.85M)
Stock-Based Compensation9.49M12.39M8.81M12.39M12.71M
Change in Working Capital9.72M(29.05M)9.52M153K(19.51M)
Accounts Receivables501K(24.85M)9.77M(11.07M)(10.15M)
Inventory(4.88M)(2.38M)1.17M764K(5.64M)
Accounts Payables41K3.79M(366K)(3.8M)3.85M
Other Working Capital14.05M(5.61M)(1.06M)14.26M(7.58M)
Other Non-Cash Items3.43M481K(213K)(788K)(41.13M)
Operating Cash Flow5.88M(73.76M)(5.74M)31.47M75.66M
Capital Expenditures(627K)(450K)(15M)(396K)0
Acquisitions (Net)00000
Purchases of Investments(141.46M)(28.89M)(31.21M)(35.27M)(153.49M)
Sales of Investments62.05M101.23M41.65M39.7M61.13M
Other Investing Activities0893K259K98K0
Investing Cash Flow(80.04M)72.78M(4.3M)4.13M(92.37M)
Debt Repayment019.54M19.95M0(7.5M)
Common Stock Issued00008.1M
Common Stock Repurchased000(10M)0
Dividends Paid00000
Other Financing Activities62.68M(12.99M)(1.58M)(1.64M)0
Financing Cash Flow62.68M6.55M18.37M(11.64M)601K
Effect of Forex Changes00000
Net Change in Cash(11.48M)5.57M8.33M23.96M(16.11M)
Free Cash Flow5.25M(74.21M)(20.74M)31.08M75.66M

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Intrinsic Alpha fair value

Locked

Current Price

$42.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.